Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adc Therapeutics Sa
(NY:
ADCT
)
3.670
-0.110 (-2.91%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adc Therapeutics Sa
< Previous
1
2
3
4
5
6
7
8
Next >
Week In Review: Full-Life Acquires Focus-X And Its Eight Radiotherapeutics In $245 Million Deal
December 04, 2022
Full-Life Technologies, a Brussels-Shanghai radiotherapeutics company, will acquire Focus-X Therapeutics for up to $245 million. Using its proprietary peptide engineering technology, Focus-X has built...
Via
Talk Markets
Stocks That Hit 52-Week Lows On Monday
November 28, 2022
On Monday, 79 companies reached new 52-week lows.
Via
Benzinga
Analyst Ratings for ADC Therapeutics
November 09, 2022
Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:
Via
Benzinga
Analyst Ratings for ADC Therapeutics
September 09, 2022
Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:
Via
Benzinga
Expert Ratings for ADC Therapeutics
September 09, 2022
ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings within the last quarter:
Via
Benzinga
ADC Therapeutics: Q2 Earnings Insights
August 09, 2022
ADC Therapeutics (NYSE:ADCT) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
November 28, 2022
From
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
November 09, 2022
Upgrades
Via
Benzinga
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 08, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 07, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
November 03, 2022
From
ADC Therapeutics SA
Via
Business Wire
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
November 02, 2022
From
ADC Therapeutics SA
Via
Business Wire
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
November 02, 2022
From
IGM Biosciences, Inc.
Via
GlobeNewswire
ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer
November 01, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
October 31, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
September 21, 2022
From
ADC Therapeutics SA
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
September 21, 2022
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago...
Via
Benzinga
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
September 16, 2022
From
ADC Therapeutics SA
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
September 14, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
September 13, 2022
From
The Schall Law Firm
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Upgrades
Via
Benzinga
Where ADC Therapeutics Stands With Analysts
September 09, 2022
Over the past 3 months, 4 analysts have published their opinion on ADC Therapeutics (NYSE:ADCT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference
September 06, 2022
From
ADC Therapeutics
Via
Business Wire
AMC Entertainment, Pharvaris And Some Other Big Stocks Moving Lower On Monday
August 22, 2022
Via
Benzinga
ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes
August 15, 2022
From
ADC Therapeutics SA
Via
Business Wire
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
August 15, 2022
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.
Via
Benzinga
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 09, 2022
From
ADC Therapeutics SA
Via
Business Wire
Earnings Outlook For ADC Therapeutics
August 08, 2022
ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that ADC...
Via
Benzinga
ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022
August 02, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors
July 27, 2022
From
ADC Therapeutics SA
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.